ArticleOncogene2002
CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potential.
Article in Oncogene, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 64 citations in OpenAlex.
- Review
- Atypical phosphatase DUSP11 inhibition promotes nc886 expression and potentiates gemcitabine-mediated cell death through NF-kB modulation.Cancer gene therapy · 2024Article
- MKP-1 overexpression is associated with chemoresistance in bladder cancer via the MAPK pathway.Oncology letters · 2020Article
- ERK Dephosphorylation through MKP1 Deacetylation by SIRT1 Attenuates RAS-Driven Tumorigenesis.Cancers · 2020Article
- DUSP1 induces apatinib resistance by activating the MAPK pathway in gastric cancer.Oncology reports · 2018Article
- The impact of phosphatases on proliferative and survival signaling in cancer.Cellular and molecular life sciences : CMLS · 2018Review
- High expression of MKP1/DUSP1 counteracts glioma stem cell activity and mediates HDAC inhibitor response.Oncogenesis · 2017Article
- Formyl peptide receptor 2 expression predicts poor prognosis and promotes invasion and metastasis in epithelial ovarian cancer.Oncology reports · 2017Article
- Role of DUSP1/MKP1 in tumorigenesis, tumor progression and therapy.Cancer medicine · 2016Review
- Microarray phosphatome profiling of breast cancer patients unveils a complex phosphatase regulatory role of the MAPK and PI3K pathways in estrogen receptor-negative breast cancers.International journal of oncology · 2014Article
- The regulatory roles of phosphatases in cancer.Oncogene · 2014Review
- Diversity and specificity of the mitogen-activated protein kinase phosphatase-1 functions.Cellular and molecular life sciences : CMLS · 2013Review
- Mitogen-activated protein kinase phosphatase (MKP)-1 in immunology, physiology, and disease.Life sciences · 2012Review
- Inside the human cancer tyrosine phosphatome.Nature reviews. Cancer · 2011Review
- Article
- Asparagine synthetase is a predictive biomarker of L-asparaginase activity in ovarian cancer cell lines.Molecular cancer therapeutics · 2008Article
- The aryl hydrocarbon receptor repressor is a putative tumor suppressor gene in multiple human cancers.The Journal of clinical investigation · 2008Article
- Targeting dual-specificity phosphatases: manipulating MAP kinase signalling and immune responses.Nature reviews. Drug discovery · 2007Review
- Biologic directed therapies in gynecologic oncology.Current oncology reports · 2003Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 3 countries.
Funding
Abstract
Although early stage ovarian cancer can be effectively treated with surgery and chemotherapy, the majority of cases present with advanced disease, which remains essentially incurable. Unfortunately, little is known about the genes important for the development and progression of this disease. In this study, the expression of 68 phosphatases was determined in immortalized ovarian epithelial cells (IOSE) and compared to ovarian cancer cell lines. CL100, a dual specificity phosphatase, displayed 10-25-fold higher expression in normal compared to malignant ovarian cell lines. Immunohistochemical staining of normal ovaries and 68 ovarian cancer specimens confirmed this differential expression. Re-expression of CL100 in ovarian cancer cells decreased adherent and non-adherent cell growth and induced phenotypic changes including loss of filopodia and lamellipodia with an associated decrease in cell motility. Induced expression of CL100 in ovarian cancer cells suppressed intraperitoneal tumor growth in nude mice. These results show for the first time that CL100 expression is altered in human ovarian cancer, that CL100 expression changes cell morphology and motility, and that it suppresses intraperitoneal growth of human ovarian epithelial cancer. These data suggest that down-regulation of CL100 may play a role in the progression of human ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.